Polycystic ovary syndrome can affect your breasts in several ways, though the connections are more nuanced than you might expect. The hormonal imbalances at the core of PCOS, particularly elevated androgens and disrupted estrogen patterns, influence breast tissue development, tenderness, and even milk production. Some of the links are well-supported, others remain genuinely uncertain, and a few widely held assumptions turn out to be wrong.
How PCOS Hormones Reach Breast Tissue
Breast tissue is highly sensitive to reproductive hormones, so the hormonal disruption that defines PCOS doesn’t stay confined to the ovaries. In PCOS, the pituitary gland produces excess luteinizing hormone, which drives the ovaries to produce more androgens than usual. Those excess androgens have a direct effect on breast tissue, but the story doesn’t stop there. Some of those androgens get converted into estrogen by an enzyme in fat and other tissues, creating a state of chronically elevated estrogen as well.
This dual hormonal excess, high androgens alongside persistently elevated estrogen, creates an unusual environment for breast tissue. In a typical menstrual cycle, estrogen and progesterone rise and fall in coordinated waves that stimulate and then quiet breast tissue each month. In PCOS, irregular or absent ovulation means progesterone levels often stay low while estrogen remains elevated, and androgen levels stay high throughout. That imbalance is the root of most breast-related effects.
Breast Development and Shape
One of the less-discussed effects of PCOS involves how breasts develop in the first place. Breast tissue growth during puberty depends heavily on estrogen and progesterone signaling, and when androgens are elevated during those formative years, the glandular tissue inside the breast may not develop as fully as it otherwise would. This can result in what clinicians call breast hypoplasia, where the breasts have less glandular tissue relative to fat and connective tissue.
A retrospective survey of women who reported insufficient milk production found that roughly two-thirds had at least one breast with features sometimes associated with underdeveloped glandular tissue, including widely spaced breasts (reported by about half) and a lack of breast growth during pregnancy (reported by nearly three-quarters). The same study identified being overweight during puberty as a risk factor for these features, which is relevant because PCOS frequently involves weight gain during adolescence.
It’s worth noting that breast shape and spacing vary enormously across the general population, and having widely spaced or tubular-appearing breasts does not mean you have PCOS. But if you have PCOS and have noticed that your breasts didn’t change much during pregnancy or seem to have a shape that’s different from what you expected, the hormonal environment during your development could be part of the explanation.
Does PCOS Make Your Breasts More Tender?
Many women with PCOS assume that their hormonal imbalances would make breast pain (mastalgia) more common. The logic seems sound: if estrogen stimulates breast tissue and PCOS involves elevated estrogen, breast tenderness should follow. But the research doesn’t actually support this assumption.
A study comparing breast pain frequency in women with PCOS to a control group found mastalgia in about a quarter of the PCOS group versus a third of controls, with no statistically significant difference between them. The researchers also found no relationship between the hormonal parameters characteristic of PCOS and the occurrence of breast pain. Despite higher levels of testosterone and other androgens in the PCOS group, those elevations didn’t translate into more breast tenderness.
This is one of those findings that catches people off guard. The likely explanation is that breast tenderness is most closely tied to cyclical progesterone changes, the kind that happen with regular ovulation. Since many women with PCOS ovulate irregularly or not at all, they may actually experience less of the cyclical breast tenderness that comes with a normal luteal phase. If you have PCOS and experience significant breast pain, it’s worth investigating on its own rather than assuming your syndrome is the cause.
Fibrocystic Changes and Benign Breast Disease
Whether PCOS increases your risk of benign breast conditions like fibrocystic changes is one of the more contested questions in this area, and the honest answer is that researchers haven’t settled it.
A cross-sectional study found fibrocystic breast disease in about 58% of women with PCOS compared to 30% of controls, suggesting that having PCOS tripled the odds of developing these benign changes. The association was strongest in the most hormonally severe form of PCOS, where rates reached over 80%.
But a 12-year follow-up study came to the opposite conclusion. Looking at rates of fibrocystic disease, fibroadenoma, breast lumps, calcification, and other benign findings, the researchers found no significantly higher prevalence of any benign breast condition in women with PCOS compared to controls. A review paper synthesizing the available literature likewise concluded that there is no clear association between PCOS and benign breast disease.
The disagreement probably comes down to differences in how these studies were designed. The study finding higher rates used ultrasound to actively screen participants, potentially catching changes that wouldn’t have been noticed otherwise. The longer follow-up study relied more on clinical reports over time. Study populations, diagnostic criteria for PCOS, and the specific phenotypes included also differed. For you as a reader, the practical takeaway is that PCOS hasn’t been shown to reliably increase your risk of benign breast disease. If you notice lumps or persistent changes, get them evaluated as you normally would, but don’t assume PCOS is driving the problem.
Breast Density on Mammograms
Dense breast tissue shows up as white areas on mammograms, and higher breast density is associated with a modestly increased risk of breast cancer as well as making cancers harder to spot on imaging. Because PCOS involves insulin resistance and metabolic features that have been linked to dense breast tissue in other contexts, researchers expected to find denser breasts in women with PCOS.
They didn’t. A case-control study specifically designed to test this hypothesis found that breast density in women with PCOS was not significantly different from controls. The researchers noted that despite the theoretical reasons to expect denser tissue, the data didn’t support it. This is useful information if you have PCOS and have been told that your mammographic density is elevated. It may be coincidental rather than syndrome-related, and the usual density-based screening recommendations apply regardless of your PCOS status.
Breastfeeding Challenges
This is where PCOS’s effect on breasts becomes most practically significant for many women. Low milk supply is one of the most common and frustrating breastfeeding challenges reported by women with PCOS, and the connection appears to be real.
The link works through at least two pathways. First, if glandular breast tissue didn’t develop fully during puberty and pregnancy due to androgen excess, there is simply less milk-producing tissue available. A systematic review noted that PCOS frequently co-occurs in women with breast hypoplasia who report insufficient milk supply, suggesting a shared hormonal root. Second, insulin resistance, which affects the majority of women with PCOS regardless of weight, appears to directly impair milk production. A study of women with low milk supply found that those showing signs of insulin resistance produced roughly half the daily milk volume of those without insulin resistance markers.
The insulin connection is particularly interesting because it suggests a potential intervention point. If insulin resistance is partly responsible for low supply, then medications that improve insulin sensitivity might help. A small pilot trial tested metformin for this purpose and found a slight trend toward maintained or increased milk output in the metformin group compared to a decline in the placebo group, but the difference wasn’t statistically significant and the study was too small to draw firm conclusions. Nearly half of women taking metformin reported nausea, which is a practical barrier. The research is still in early stages, but it points toward insulin resistance as a modifiable factor rather than something women simply have to accept.
If you have PCOS and are planning to breastfeed, it helps to be aware of this possibility early. Working with a lactation consultant before delivery, having a breast pump ready, and discussing your PCOS status with your care team can all improve outcomes. Low supply in this context is not a reflection of effort or commitment. It’s a physiological constraint that some women with PCOS face.
Breast Cancer Risk
Given the hormonal upheaval involved in PCOS, particularly the chronic estrogen exposure without regular progesterone opposition, it would be reasonable to worry about breast cancer risk. Unopposed estrogen is a well-established risk factor for certain hormone-sensitive cancers, and PCOS does significantly increase the risk of endometrial cancer for exactly this reason. But the breast cancer picture looks different.
Two separate meta-analyses have examined this question, and both came to the same conclusion. One pooled results from case-control and cohort studies and found no significant association between PCOS and breast cancer. The other, a systematic review covering multiple cancer types, found that while PCOS significantly increased endometrial cancer risk, breast cancer risk showed no significant difference between women with PCOS and controls, even when the analysis was restricted to younger women.
Why would the same hormonal environment that increases endometrial cancer risk not increase breast cancer risk? The answer likely involves androgens. Breast tissue and endometrial tissue respond to androgens differently. In the breast, androgens appear to have an inhibitory effect on the growth of mammary cells, which may counterbalance the cancer-promoting effects of estrogen. However, some research notes that higher levels of bioavailable androgens have been associated with breast cancer recurrence, possibly because androgens can still be converted to estrogens within breast tissue itself. The relationship is complicated enough that a review characterizing it as “controversial” pointed out that low levels of sex hormone-binding globulin, a common finding in PCOS, could theoretically influence cancer risk through altered hormone availability.
A comprehensive review of breast cancer risk in endocrine conditions concluded that while definitive evidence of elevated breast cancer risk in PCOS is lacking, individualized screening and careful management of hormone therapy remain important given the complex interplay of hormonal and metabolic factors. In plain terms, PCOS alone doesn’t seem to raise your breast cancer risk, but you should still follow standard screening guidelines and discuss any additional risk factors with your doctor.
What Androgen Exposure Does to Breast Tissue Over Time
An indirect way to understand how elevated androgens affect breasts comes from research on transgender men receiving testosterone as part of gender-affirming hormone therapy. While this population differs from women with PCOS in many ways, the breast tissue changes observed offer a window into what sustained androgen exposure does.
Studies of breast tissue in transgender men who had been on testosterone therapy for extended periods found a consistent pattern. Glandular tissue shrank, and fibrous connective tissue expanded to replace it. In one large case series, the vast majority showed some degree of lobular atrophy, meaning the milk-producing structures had reduced in size and activity. Fibrocystic changes were found in some participants, but no cases of atypical hyperplasia, in situ carcinoma, or malignant changes were observed. The overall picture was one of breast tissue becoming less glandular and more fibrous under androgen influence, without becoming cancerous.
For women with PCOS, the androgen levels involved are much lower than therapeutic testosterone doses, but the direction of effect is consistent with what’s seen clinically: less glandular development, potentially more fibrous tissue, and no clear increase in malignancy risk. This also helps explain the breastfeeding difficulties described earlier, as less glandular tissue means less capacity to produce milk.
Prenatal Androgen Exposure and Breast Development
Research in animal models suggests that the timing of androgen exposure matters enormously for breast development. In a study exposing female rats to androgens at different stages of prenatal development, early exposure completely prevented nipple formation, while later exposure had no effect on nipple number. This finding underscores just how sensitive mammary tissue development is to the hormonal environment during critical windows.
In humans, daughters of women with PCOS are exposed to higher-than-normal androgen levels in utero, which has led researchers to investigate whether this prenatal environment programs breast tissue development before the child is even born. The research is still preliminary, and you can’t directly extrapolate rat findings to humans, but it raises an intriguing possibility: that some of the breast-related features seen in women with PCOS, such as underdeveloped glandular tissue, may have roots that extend all the way back to fetal development rather than beginning at puberty.
Body Image and the Psychological Dimension
PCOS affects how women feel about their bodies in ways that go beyond any single symptom. A study comparing body image in women with and without PCOS found significantly worse scores across every measured dimension of body satisfaction in the PCOS group, even after adjusting for age, weight, race, income, and pregnancy history. Depressive symptoms were more common (about 28% versus 19% of controls), as were anxiety symptoms (roughly three-quarters of the PCOS group versus just over half of controls). The researchers found that body image distress fully explained the connection between PCOS and anxiety, and partially explained the connection with depression.
Breasts are part of this picture, though not always in the way you might expect. Some women with PCOS experience breast enlargement related to weight gain and find that their breast size fluctuates with metabolic changes. Others notice that their breasts didn’t develop as expected during puberty or didn’t grow during pregnancy. Both situations can contribute to feeling that your body isn’t behaving the way it should. The visible symptoms of PCOS, including acne, excess hair growth, hair thinning, and weight changes, tend to cluster in areas tied to femininity and self-image, and breast-related concerns fit into that broader pattern of distress.
Addressing body image in PCOS often requires more than managing individual symptoms. If breast-related concerns are contributing to how you feel about your body, bringing them up with your healthcare provider is worthwhile. They tend to get less attention than other PCOS symptoms like irregular periods or fertility, but they affect daily life just as much for some women.
Screening and What to Discuss With Your Doctor
PCOS does not currently warrant any change to standard breast cancer screening timelines. The evidence consistently shows no significant elevation in breast cancer risk, so the usual age-based mammography recommendations apply. Where PCOS does warrant a conversation is around benign breast changes and breastfeeding planning.
If you notice new lumps, persistent breast changes, or unusual discharge, get them evaluated the same way anyone would. Don’t dismiss breast symptoms as “just PCOS” and don’t assume PCOS makes benign findings inevitable. The evidence on fibrocystic changes is mixed enough that neither assumption serves you well.
For breastfeeding, the most useful step is proactive planning. Let your obstetric team and any lactation support know about your PCOS diagnosis early. If you have signs of insulin resistance, discuss whether any interventions before or after delivery might support milk production. Supplementation plans and realistic expectations set before the baby arrives can reduce both the practical and emotional stress of low supply if it occurs. None of this guarantees a particular outcome, but being prepared is consistently better than being surprised.